How big is the United States Insulin Drugs And Delivery Devices Market?

APR 2023: FDA Approved Medtronic MiniMed 780G System Insulin Pump with Meal Detection Technology Featuring 5-Minute Auto Corrections.
NOV 2022: FDA Approves Second Interchangeable Insulin Product, Rezvoglar (insulin glargine-aglr). Rezvoglar is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

The United States Insulin Drugs And Delivery Devices Market size is expected to reach USD 19.70 billion in 2024 and grow at a CAGR of 2.70% to reach USD 22.5 billion by 2029. Read More

What is the current United States Insulin Drugs And Delivery Devices Market size?

In 2024, the United States Insulin Drugs And Delivery Devices Market size is expected to reach USD 19.70 billion. Read More

Who are the key players in United States Insulin Drugs And Delivery Devices Market?

Novo Nordisk, Medtronics, Sanofi, Eli Lily and Ypsomped are the major companies operating in the United States Insulin Drugs And Delivery Devices Market. Read More

What years does this United States Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?

In 2023, the United States Insulin Drugs And Delivery Devices Market size was estimated at USD 19.17 billion. The report covers the United States Insulin Drugs And Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the United States Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More